Protecting the public's health: critical functions of the Section 317 Immunization Program-a report of the National Vaccine Advisory Committee.
出版信息
Public Health Rep. 2013 Mar-Apr;128(2):78-95. doi: 10.1177/003335491312800203.
Abstract
摘要
相似文献
1
Protecting the public's health: critical functions of the Section 317 Immunization Program-a report of the National Vaccine Advisory Committee.
Public Health Rep. 2013 Mar-Apr;128(2):78-95. doi: 10.1177/003335491312800203.
2
Section 317 immunization program: protecting a national asset.
Public Health Rep. 2013 Mar-Apr;128(2):96-8. doi: 10.1177/003335491312800204.
3
A message from the editor.
Public Health Rep. 2013 Mar-Apr;128(2):75. doi: 10.1177/003335491312800201.
4
Evaluation of the 2010 National Vaccine Plan Mid-course Review: Recommendations From the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on February 7, 2017.
Public Health Rep. 2017 Jul/Aug;132(4):411-430. doi: 10.1177/0033354917714233. Epub 2017 Jun 23.
5
Adult immunization: what can we learn from the childhood immunization program?
Clin Infect Dis. 2007 Jun 15;44(12):1532-5. doi: 10.1086/519543. Epub 2007 May 14.
6
7
Update From the Advisory Committee on Immunization Practices.
J Pediatric Infect Dis Soc. 2016 Dec;5(4):349-355. doi: 10.1093/jpids/piw057. Epub 2016 Oct 7.
8
9
Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices.
MMWR Morb Mortal Wkly Rep. 2003 Apr 4;52(13):282-4.
10
Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years-United States, 2014.
Am J Transplant. 2014 Apr;14(4):972-3. doi: 10.1111/ajt.12730.
引用本文的文献
1
Analysis of the Federal Section 317 Immunization Program and Routine Adult Immunization Activities, United States, 2022-2023.
Public Health Rep. 2024 Sep-Oct;139(5):626-634. doi: 10.1177/00333549241236085. Epub 2024 Mar 19.
2
County-Level Factors Associated With Influenza and COVID-19 Vaccination in Indiana, 2020‒2022.
Am J Public Health. 2024 Apr;114(4):415-423. doi: 10.2105/AJPH.2023.307553. Epub 2024 Feb 22.
3
Vaccine uptake and barriers to vaccination among at-risk adult populations in the US.
Hum Vaccin Immunother. 2022 Nov 30;18(5):2055422. doi: 10.1080/21645515.2022.2055422. Epub 2022 May 10.
4
COVID-19 Vaccines in Indonesia: Knowledge, Attitudes, and Acceptance Among Dental Professionals.
Front Med (Lausanne). 2021 Dec 21;8:784002. doi: 10.3389/fmed.2021.784002. eCollection 2021.
5
Recent Development of Ruminant Vaccine Against Viral Diseases.
Front Vet Sci. 2021 Nov 3;8:697194. doi: 10.3389/fvets.2021.697194. eCollection 2021.
6
Strategies for Successful Vaccination Among Two Medically Underserved Populations: Lessons Learned From Hepatitis A Outbreaks.
Am J Public Health. 2021 Aug;111(8):1409-1412. doi: 10.2105/AJPH.2021.306308.
7
Human papillomavirus vaccination practices and perceptions among Ghanaian Healthcare Providers: A qualitative study based on multi-theory model.
PLoS One. 2020 Oct 16;15(10):e0240657. doi: 10.1371/journal.pone.0240657. eCollection 2020.
8
Progress in Vaccine-Preventable and Respiratory Infectious Diseases-First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006-2015.
Emerg Infect Dis. 2018 Jul;24(7):1178-1187. doi: 10.3201/eid2407.171699.
9
Examination of universal purchase programs as a driver of vaccine uptake among US States, 1995-2014.
Vaccine. 2018 Jun 27;36(28):4032-4038. doi: 10.1016/j.vaccine.2018.05.103.
10
The National Vaccine Advisory Committee at 30: Impact and opportunity.
Vaccine. 2018 Mar 7;36(11):1330-1344. doi: 10.1016/j.vaccine.2018.01.068.
本文引用的文献
1
Economic evaluation of the routine childhood immunization program in the United States, 2009.
Pediatrics. 2014 Apr;133(4):577-85. doi: 10.1542/peds.2013-0698. Epub 2014 Mar 3.
2
Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.
MMWR Morb Mortal Wkly Rep. 2012 Jun 1;61(21):394-5.
3
Middle school vaccination requirements and adolescent vaccination coverage.
Pediatrics. 2012 Jun;129(6):1056-63. doi: 10.1542/peds.2011-2641. Epub 2012 May 7.
4
Measles - United States, 2011.
MMWR Morb Mortal Wkly Rep. 2012 Apr 20;61:253-7.
5
A pathway to leadership for adult immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 14, 2011.
Public Health Rep. 2012 Jan-Feb;127 Suppl 1(Suppl 1):1-42. doi: 10.1177/00333549121270s101.
6
Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
MMWR Morb Mortal Wkly Rep. 2011 Nov 4;60(43):1477-81.
7
Strengthening the U.S. vaccine and immunization enterprise: the role of the National Vaccine Advisory Committee.
Public Health Rep. 2011 Jan-Feb;126(1):4-8. doi: 10.1177/003335491112600103.
8
Measles in the United States during the postelimination era.
J Infect Dis. 2010 Nov 15;202(10):1520-8. doi: 10.1086/656914. Epub 2010 Oct 7.
9
Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
MMWR Morb Mortal Wkly Rep. 2010 Mar 12;59(9):258-61.
10
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.
J Infect Dis. 2010 Jan 1;201(1):32-41. doi: 10.1086/648593.
Zotero 插件